Extended release immunomodulatory implant to facilitate bone morphogenesis

Patent metadata

Field	Value
Publication number	US-11779683-B2
Application number	US-202016790866-A
Country	US
Kind code	B2
Filing date	Feb 14, 2020
Priority date	Apr 8, 2019
Publication date	Oct 10, 2023
Grant date	Oct 10, 2023

Abstract

An extended release immunomodulatory implant operatively arranged to facilitate bone morphogenesis, including an inner portion including at least one growth factor, a first layer including at least one of one or more interleukins and capsaicin, and a second layer including an antigen operatively arranged to activate an innate immune system.

First claim

What is claimed is:

1. An extended release immunomodulatory implant operatively arranged to facilitate bone morphogenesis, comprising:
an inner portion including at least one growth factor;
a first layer arranged on the inner portion and including at least one of one or more interleukins and capsaicin; and,
a second layer arranged on the first layer and including an antigen operatively arranged to activate an innate immune system, the second layer being at least partially phagocytosable.

2. The implant as recited in claim 1 , wherein the at least one growth factor comprises at least one of a concentrated growth factor (CGF) and a vascular endothelial growth factor (VEGF).

3. The implant as recited in claim 1 , wherein the implant comprises at least one of inert beta-tricalcium phosphate, calcium carbonate, silicon, polylactic-co-glycolic acid, and hydroxyapatite.

4. The implant as recited in claim 3 , wherein the implant consists of inert beta-tricalcium phosphate, calcium carbonate, silicon, and polylactic-co-glycolic acid, wherein the silicon is 1% by weight.

5. The implant as recited in claim 1 , wherein the first layer comprises at least one of interleukin 4, interleukin 10, and interleukin 13.

6. The implant as recited in claim 1 , wherein the antigen comprises at least one of lipopolysaccharide and lipoteichoic acid.

7. The implant as recited in claim 6 , wherein the antigen consists of a mixture of:
50% by weight lipopolysaccharide; and,
50% by weight lipoteichoic acid.

8. The implant as recited in claim 6 , wherein the antigen consists of 100% by weight lipopolysaccharide.

9. The implant as recited in claim 6 , wherein the antigen consists of 100% by weight lipoteichoic acid.

10. The implant as recited in claim 6 , wherein the lipopolysaccharide is derived from Escherichia coli.

11. The implant as recited in claim 6 , wherein the lipoteichoic acid is derived from Staphylococcus aureus.

12. The implant as recited in claim 1 , wherein the first layer comprises a first density and the second layer comprises a second density, the first density being greater than the second density.

13. The implant as recited in claim 1 , wherein the inner portion comprises a first porosity and the first layer comprises a second porosity, the second porosity being greater than the first porosity.

14. The implant as recited in claim 1 , wherein the first layer comprises at least one of inert beta-tricalcium phosphate, calcium carbonate, silicon, polylactic-co-glycolic acid, and hydroxyapatite, impregnated with the one or more interleukins.

15. The implant as recited in claim 1 , wherein the second layer comprises at least one of inert beta-tricalcium phosphate, calcium carbonate, silicon, polylactic-co-glycolic acid, and hydroxyapatite, impregnated with the antigen.

16. The implant as recited in claim 1 , wherein the first layer is arranged radially outward of the inner portion and the second layer is arranged radially outward of the first layer.

17. The implant as recited in claim 16 , further comprising an innermost portion arranged radially inward of the inner portion, wherein the innermost portion comprises at least one of an interleukin and capsaicin.

18. The implant as recited in claim 17 , wherein:
the innermost portion comprises interleukin 10 and interleukin 13; and,
the first layer comprises interleukin 4.

19. The implant as recited in claim 1 , wherein:
the inner portion comprises hydroxyapatite;
the first layer comprises beta-tricalcium phosphate including one or more interleukins; and,
the second layer comprises at least one of lipopolysaccharide, lipoteichoic acid, and interferon gamma.

20. The implant as recited in claim 1 , wherein the implant comprises at least one of allograft bone, autograft bone, xenograft bone, a titanium implant, a polyether ether ketone (PEEK) implant, and synthetic bone void filler.

21. An extended release immunomodulatory implant operatively arranged to facilitate bone morphogenesis, comprising:
an implant matrix including a first material, the implant matrix including:
an inner portion including at least one of a concentrated growth factor (CGF) and a vascular endothelial growth factor (VEGF);
a first layer arranged radially outward of the inner portion and including one or more interleukins; and,
a second layer arranged radially outward of the first layer and including an antigen operatively arranged to activate the innate immune system.

22. The implant as recited in claim 21 , wherein the first material comprises at least one of inert beta-tricalcium phosphate, calcium carbonate, silicon, polylactic-co-glycolic acid, and hydroxyapatite.

23. The implant as recited in claim 22 , wherein the first material consists of inert beta-tricalcium phosphate, calcium carbonate, silicon, and polylactic-co-glycolic acid, wherein the silicon is 1% by weight.

24. The implant as recited in claim 22 , wherein the second layer consists of a mixture of:
50% by weight lipopolysaccharide; and,
50% by weight lipoteichoic acid.

25. The implant as recited in claim 22 , wherein the first layer is impregnated with the at least one of interleukin 4, interleukin 10, and interleukin 13.

26. The implant as recited in claim 22 , wherein the second layer is impregnated with the at least one of lipopolysaccharide and lipoteichoic acid.

27. The implant as recited in claim 21 , further comprising an innermost core including at least one of interleukin 4, interleukin 10, and interleukin 13.

Assignees

• Suddaby Loubert S

Inventors

• Suddaby Loubert S

Classifications

• A61L27/54 Primary

  Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} · CPC title

• A61K39/39

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

• A61L27/446

  with other specific inorganic fillers other than those covered by A61L27/443 or A61L27/46 · CPC title

• A61L27/46

  with phosphorus-containing inorganic fillers · CPC title

• A61L27/48

  with macromolecular fillers · CPC title